The mean age of diagnosis of AA amyloidosis was 59.6 years, with the average time from diagnosis to confirmation being 23.4 months. Female sex, AA amyloidosis in patient's family members, and high blood levels of uric acid were associated with an earlier age of diagnosis of AA amyloidosis.
Amyloidosis is an incurable disease, but one of the longest-lived, and even some patients who have a long survival can be effectively treated. Patients should be informed about this before being diagnosed with amyloidosis. At this stage, some patients who have high-grade primary amyloidosis of a non-AAB subtype may succumb to systemic amyloidosis. The key problem is to identify a patient with amyloidosis that will ultimately succumb to the disease without treatment. If and when that patient is identified, some treatment can be started.
Drugs and toxins can cause amyloidosis. Although exact mechanisms are not known, many of these cases may result in multiple organ failure, hence requiring [transplant](https://www.withpower.com/clinical-trials/transplant)ation if possible. Because many of these conditions are so rare, and amyloidosis is also very rare, it is impossible to determine how many people will have amyloidosis as a side effect of drugs and toxins. Some common medications that are reported as having a known association with amyloidosis are tacrolimus, levofloxacin, and amiodarone.
Different types of amyloidoses or protein deposits in tissues may cause problems for different organs. Deposits in the kidneys cause kidney problems, heart problems, or in the liver and lymph nodes, they may lead to an enlarged spleen or lymph nodes and increase the risk of cancer.
No definitive therapy has been found for AL or AA amyloidosis. In contrast, treatment is determined by the type of amyloidosis (AL, AA, or AA variants of amyloidosis). For AA amyloidosis, several different treatments have been employed. In contrast, there has been no conclusive finding of effective treatment for AL amyloidosis. Despite the limited number of cases, some observations can be made regarding the treatment of amyloidosis based on the types (AL, AL variant, AA, AA variant, AA variant, etc.) of amyloidosis. Although a few cases have been reported, no one has proven effective in treating AL amyloidosis or AL variant amyloidosis.
The symptoms reported by patients with amyloidosis are mainly nonspecific. The signs of this serious condition are varied according to the subtype of amyloidosis. Cardiovascular involvement is the most common cause of death.
cael-101 may have a small positive effect in treating the patient's fatigue and QOL with moderate improvement in EF and HRQoL scores. Cael-101 is a safe, well tolerated, and effective agent for treating this rare disease and has the potential to become standard of care for patients with AL amyloidosis.
The study demonstrates significant improvement in disease severity in mice treated with Cael-101. However, in view of the short time period between treatment and start of symptoms (4—6 weeks), it is not yet clear what constitutes the optimal time for treatment and how long after first symptoms it takes for the improvement to start. Further investigations have to be performed to determine if Cael-101 can prevent complications of AL amyloidosis, such as amyloid-associated heart disease or kidney failure, and if that can be achieved within the time frame of this study.
Caer-101, at a dose of 25MBq or 40MBq administered at intervals of 6 or 12 minutes, was tolerated well by volunteers. The most common toxic effects were those that were previously observed with other forms of caer-101, including nausea and diarrhea. Caer-101 was well-tolerated and appeared to have a clear safety profile.
There are many interesting new treatments for treating amyloidosis, but more studies need to be conducted on the topic. A new treatment that has been tried successfully is Intralase treatment. The first successful attempt of Intralase had positive results, in which patients were able to keep up with their activities after an Intralase treatment. It is important to educate patients, because if they have undergone an Intralase treatment, they will receive some information that would help them to understand the consequences and advantages of their treatment. Furthermore, if you are choosing the treatment option of Intralase, it is good to choose a group of specialists from multiple disciplines.
It is not possible to answer the question of what the future holds for cael-101, as there are no clinical trials of cael-101 yet. The overall data on the efficacy of cael-101 in clinical trials in combination with other chemotherapies show a reasonable chance that a clinical trial of cael-101 will appear in the near future.
Survival is low. If the survival time exceeds 5 years, the mortality rate is low, although this may be due in part to the use of chemotherapy.